NanoTherm
Commercial- Indications
- Glioblastoma
Company intelligence / Profile preview
MagForce
Berlin, Berlin, Germanymagforce.com.tw ↗
- Ownership
- Private
- Employees
- ~40
- Development stage
- Commercial
01
Overview
MagForce has developed and commercialized the first EU-approved nanotechnology-based medical device for treating solid brain tumors using magnetic hyperthermia. The company’s proprietary NanoTherm therapy involves injecting superparamagnetic iron oxide nanoparticles into a tumor and heating them with an alternating magnetic field to destroy or sensitize tumor cells. Over 100 patients have been treated in Europe; clinical studies are ongoing in the US for prostate cancer. Clinical adoption has been slow but supported by strong IP and strategic investment from Mithril Capital Management.
- Therapeutic areas
- Oncology
- Modalities
- DeviceNanoparticle (specifically superparamagnetic iron oxide nanoparticles)Non-pharmacological therapy (magnetic hyperthermia)
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
1 asset03
Partnerships
Mithril Capital Management (strategic investor/partner in US subsidiary)
Beyond the preview
Go deeper on MagForce.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MagForce.